Evidence map›Paper›PMID 32357804›Full record

ArticleExpert opinion on drug delivery2020

Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges.

Chalet Tan, Thomas A Waldmann

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Optimized expression of human interleukin-15 inBiotechnology reports (Amsterdam, Netherlands) · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chalet TanDepartment of Pharmaceutics and Drug Delivery, University of Mississippi , Oxford, MS, USA.
Thomas A WaldmannLymphoid Malignancies Branch, Center of Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.ORCID 0000-0003-4500-6660

Funding

Interleukin-15 Production for Treatment of Patients with Metastatic MalignancyZIBBC010906 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALDMANN, THOMAS · 2009 to 2022
$29.3M
Interleukin-15 Production for Treatment of Patients with Metastatic MalignancyZ01BC010906 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALDMANN, THOMAS · 2008 to 2008
$2.0M
Intramural NIH HHS Z01 BC010906Intramural NIH HHS ZIB BC010906
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32357804
PMCPMC7374014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.